AstraZeneca has decided to trim back its 2015 alliance with Inovio Pharmaceuticals, which focused on combining the biotech’s DNA cancer vaccines with AZ’s cancer immunotherapies.
The FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) patients who have received two prior therapies.
Eli Lilly has signed another bolt-on deal to bulk up its pipeline, this time paying $47.5 million upfront for rights to a non-opioid analgesic drug developed by US biotech Centrexion Therap
Newron has been forced to delay the start of a pivotal trial of its schizophrenia candidate evenamide – tipped as a potential blockbuster – after an FDA query about safety data from animal
The FDA has approved Novartis’ breast cancer drug Piqray (alpelisib), making it the first marketed treatment targeting the PIK3CA mutation in this disease.
After all the anticipation, Novartis has the FDA approval it has been seeking for Zolgensma, its gene therapy for spinal muscular atrophy, and has priced it at the low end of expectations.<
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.